Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20160-20176

  Gu, Qingyang ^a,d   Zhang, Bin ^a,d   Sun, Hongye ^a,d   Xu, Qiang ^a,d   Tan, Yexiong ^b,d   Wang, Guan ^a,d   Luo, Qin ^a,d   Xu, Weiguo ^a,d   Yang, Shuqun ^a,d   Li, Jian ^a,d   Fu, Jing ^b,d   Chen, Lei ^b,d   Yuan, Shengxian ^b,d   Liang, Guibai ^a,d   Ji, Qunsheng ^a,d   Chen, Shu Hui ^a,d   Chan, Chi Chung ^a,d   Zhou, Weiping ^b,d   Xu, Xiaowei ^c,d   Wang, Hongyang ^b,d   Fang, Douglas D ^a,d   more..

^a WUXI APPTEC   (China)

^b Eastern Hepatobiliary Surgery Hospital   (China)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d China Novartis Institutes for BioMedical Research Co Ltd   (China)

Author keywords

Copy number alterations (CNA); Hepatocellular carcinoma (HCC); Patient derived xenograft (PDX) tumor model; Single

Indexed keywords

ALPHA FETOPROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HERPESVIRUS ENTRY MEDIATOR; LENVATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMAD4 PROTEIN; SORAFENIB; TUBERIN; UVOMORULIN;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARID1B GENE; ARTICLE; AXIN1 GENE; BCL9 GENE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CDKN2A GENE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; EXOME; FEMALE; FGF19 GENE; FLOW CYTOMETRY; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IGF2R GENE; INDEL MUTATION; JAK1 GENE; KRAS GENE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MET GENE; MOUSE; MTDH GENE; NONHUMAN; PBX1 GENE; RAP1GDS1 GENE; RB1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP73 GENE; TUMOR GENE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG SCREENING; GENETICS; GENOMICS; LIVER TUMOR; NUDE MOUSE; PATHOLOGY; SCID MOUSE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION; GENOMICS; HUMANS; LIVER NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, FIBROBLAST GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940214274     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3969     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127.
3. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7:448-458.
4. Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012. current status and future perspectives. Semin Oncol. 2012; 39:493-502.
5. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116:4590-4596.
6. Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011; 16:1270-1279.
7. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012; 57:101-107.
8. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2012; 9:32-43.
9. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9:338-350.
10. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996; 66:239-243.
11. Gao YS, Chen XP, Li KY, Wu ZD. Nude mice model of human hepatocellular carcinoma via orthotopic implantation of histologically intact tissue. World J Gastroenterol. 2004; 10:3107-3111.
12. Armengol C, Tarafa G, Boix L, Sole M, Queralt R, Costa D, Bachs O, Bruix J, Capella G. Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res. 2004; 10:2150-2157.
13. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res. 2006; 12:4306-4314.
14. Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol. 2014; 9:285-294.
15. Fang DD, Gao YB, Xu Q, Sun HY, Zhang B, Chen ZL, et al. Identification of somatic mutations in esophageal squamous cell carcinoma and corresponding xenograft by next-generation sequencing [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012.
16. Xu Q, Wang G, Fang DD, Gao YB, Chen YD, Sun LL, et al. Deep sequencing of Xenografts and case-matched blood and primary tumors reveals a 20 folds enrichment of loss of heterozygosity versus somatic mutations suggesting LOH plays an ever important role in tumorigenesis [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012.
17. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012; 44:760-764.
18. Zhang Z. Genomic landscape of liver cancer. Nat Genet. 2012; 44:1075-1077.
19. Li S, Mao M. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett. 2013; 340:247-253.
20. Wang K, Lim HY, Shi S, Lee J, Deng S, Xie T, Zhu Z, Wang Y, Pocalyko D, Yang WJ, Rejto PA, Mao M, Park CK, Xu J. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 2013; 58:706-717.
21. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012; 18:5314-5328.
22. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF. Lentivirusmediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007; 46:200-208.
23. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011; 71:4028-4039.
24. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012; 56:622-631.
25. Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, Ogawa M, Yokosuka O, Iwama A. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol. 2010; 52:854-863.
26. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumorinitiating hepatocellular carcinoma cells. Int J Cancer. 2012; 130:2557-2567.
27. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC. Cloning of the t(1, 5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003; 102:4187-4190.
28. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007; 30:97-103.
29. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45:478-486.
30. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
31. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150:1107-1120.
32. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S, Basler K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002; 109:47-60.
33. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB, Sarkar D. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009; 119:465-477.
34. Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, Lee CK, Somani A, Lee HS, Kalpana R, Yu K, Tan PH, Wu J, Soong R, Lee MH, Hor H, Soo KC, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008; 49:52-60.
35. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14:5124-5130.
36. Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 2009; 13:1371-1380.
37. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14:6146-6153.
38. Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Curr Cancer Drug Targets. 2011; 11:944-953.
39. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010; 52:79-87.
40. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD244 (ARRY-14288) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6:138-146.
41. Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets. 2009; 9:738-747.
42. Huynh H, Ong R, Soo KC. Foretinib demonstrates antitumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012; 15:59-70.
43. Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012; 56:595-601.
44. Lenvatinib approved for certain thyroid cancers: Cancer Discov. 2015; 5:338.
45. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3:264-279.